Cargando…
Is there a distinction between malaria treatment and intermittent preventive treatment? Insights from a cross-sectional study of anti-malarial drug use among Ugandan pregnant women
BACKGROUND: In Uganda, treatment of clinical malaria and intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) are common during pregnancy. As a result, both formal and informal reports from antenatal sources suggest possible misuse of SP for malaria treatment among pregnant women....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424832/ https://www.ncbi.nlm.nih.gov/pubmed/25935720 http://dx.doi.org/10.1186/s12936-015-0702-7 |
_version_ | 1782370385406197760 |
---|---|
author | Odongo, Charles O Bisaso, Kuteesa R Kitutu, Freddy Obua, Celestino Byamugisha, Josaphat |
author_facet | Odongo, Charles O Bisaso, Kuteesa R Kitutu, Freddy Obua, Celestino Byamugisha, Josaphat |
author_sort | Odongo, Charles O |
collection | PubMed |
description | BACKGROUND: In Uganda, treatment of clinical malaria and intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) are common during pregnancy. As a result, both formal and informal reports from antenatal sources suggest possible misuse of SP for malaria treatment among pregnant women. The objective of this study was to investigate anti-malarial drug use patterns among women who had recently suffered malaria illness before and during pregnancy. METHODS: A cross-sectional study in which a structured questionnaire (interviewer-administered) was used to collect data from pregnant women attending an urban antenatal clinic. Details of medicines used to treat malaria episodes suffered before and during pregnancy were captured. A first order Markov probability model was used to estimate probabilities of transitioning between treatment choices made before and during pregnancy. Logistic regression was used to explore whether demographic and obstetric characteristics were associated with transition patterns. RESULTS: Seven hundred women were interviewed among whom 428 had suffered malaria in both instances. Three hundred thirty of these could recall the medicines used in both instances. Women who used ACT/QNN (correct choice) before pregnancy had higher probabilities of transitioning to SP than staying on ACT/QNN during pregnancy (0.463 versus 0.451). Access of medicines from private outlets (clinics and pharmacies) were more than nine times predictive of receiving correct medicines (p=0.035 and p=0.039 respectively). Access of medicines from clinics was 5.9 times protective against receiving SP for malaria treatment (p=0.033). Among those who used SP before pregnancy, there was a 0.75 probability of staying on it during pregnancy. None of the factors explored could explain this observation. CONCLUSION: Use of SP for malaria treatment is common during pregnancy. This may be contributing to adverse pregnancy outcomes. Antenatal care providers should endeavour to emphasize the distinction between treatment and prevention of malaria during pregnancy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0702-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4424832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44248322015-05-09 Is there a distinction between malaria treatment and intermittent preventive treatment? Insights from a cross-sectional study of anti-malarial drug use among Ugandan pregnant women Odongo, Charles O Bisaso, Kuteesa R Kitutu, Freddy Obua, Celestino Byamugisha, Josaphat Malar J Research BACKGROUND: In Uganda, treatment of clinical malaria and intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) are common during pregnancy. As a result, both formal and informal reports from antenatal sources suggest possible misuse of SP for malaria treatment among pregnant women. The objective of this study was to investigate anti-malarial drug use patterns among women who had recently suffered malaria illness before and during pregnancy. METHODS: A cross-sectional study in which a structured questionnaire (interviewer-administered) was used to collect data from pregnant women attending an urban antenatal clinic. Details of medicines used to treat malaria episodes suffered before and during pregnancy were captured. A first order Markov probability model was used to estimate probabilities of transitioning between treatment choices made before and during pregnancy. Logistic regression was used to explore whether demographic and obstetric characteristics were associated with transition patterns. RESULTS: Seven hundred women were interviewed among whom 428 had suffered malaria in both instances. Three hundred thirty of these could recall the medicines used in both instances. Women who used ACT/QNN (correct choice) before pregnancy had higher probabilities of transitioning to SP than staying on ACT/QNN during pregnancy (0.463 versus 0.451). Access of medicines from private outlets (clinics and pharmacies) were more than nine times predictive of receiving correct medicines (p=0.035 and p=0.039 respectively). Access of medicines from clinics was 5.9 times protective against receiving SP for malaria treatment (p=0.033). Among those who used SP before pregnancy, there was a 0.75 probability of staying on it during pregnancy. None of the factors explored could explain this observation. CONCLUSION: Use of SP for malaria treatment is common during pregnancy. This may be contributing to adverse pregnancy outcomes. Antenatal care providers should endeavour to emphasize the distinction between treatment and prevention of malaria during pregnancy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0702-7) contains supplementary material, which is available to authorized users. BioMed Central 2015-05-03 /pmc/articles/PMC4424832/ /pubmed/25935720 http://dx.doi.org/10.1186/s12936-015-0702-7 Text en © Odongo et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Odongo, Charles O Bisaso, Kuteesa R Kitutu, Freddy Obua, Celestino Byamugisha, Josaphat Is there a distinction between malaria treatment and intermittent preventive treatment? Insights from a cross-sectional study of anti-malarial drug use among Ugandan pregnant women |
title | Is there a distinction between malaria treatment and intermittent preventive treatment? Insights from a cross-sectional study of anti-malarial drug use among Ugandan pregnant women |
title_full | Is there a distinction between malaria treatment and intermittent preventive treatment? Insights from a cross-sectional study of anti-malarial drug use among Ugandan pregnant women |
title_fullStr | Is there a distinction between malaria treatment and intermittent preventive treatment? Insights from a cross-sectional study of anti-malarial drug use among Ugandan pregnant women |
title_full_unstemmed | Is there a distinction between malaria treatment and intermittent preventive treatment? Insights from a cross-sectional study of anti-malarial drug use among Ugandan pregnant women |
title_short | Is there a distinction between malaria treatment and intermittent preventive treatment? Insights from a cross-sectional study of anti-malarial drug use among Ugandan pregnant women |
title_sort | is there a distinction between malaria treatment and intermittent preventive treatment? insights from a cross-sectional study of anti-malarial drug use among ugandan pregnant women |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424832/ https://www.ncbi.nlm.nih.gov/pubmed/25935720 http://dx.doi.org/10.1186/s12936-015-0702-7 |
work_keys_str_mv | AT odongocharleso isthereadistinctionbetweenmalariatreatmentandintermittentpreventivetreatmentinsightsfromacrosssectionalstudyofantimalarialdruguseamongugandanpregnantwomen AT bisasokuteesar isthereadistinctionbetweenmalariatreatmentandintermittentpreventivetreatmentinsightsfromacrosssectionalstudyofantimalarialdruguseamongugandanpregnantwomen AT kitutufreddy isthereadistinctionbetweenmalariatreatmentandintermittentpreventivetreatmentinsightsfromacrosssectionalstudyofantimalarialdruguseamongugandanpregnantwomen AT obuacelestino isthereadistinctionbetweenmalariatreatmentandintermittentpreventivetreatmentinsightsfromacrosssectionalstudyofantimalarialdruguseamongugandanpregnantwomen AT byamugishajosaphat isthereadistinctionbetweenmalariatreatmentandintermittentpreventivetreatmentinsightsfromacrosssectionalstudyofantimalarialdruguseamongugandanpregnantwomen |